The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
H
Heba Ismail
Primary Investigator
Overview
Obesity prevalence in persons with T1D has increased, which further complicates managementd risk for complications. The proposed study is relevant to public health because it helps
us understand the role of the gut microbiome in disease pathophysiology in T1D youth withbesity as well as potential mechanisms to modify disease.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Type 1 Diabetes, Obesity
-
Age: Between 11 Years - 18 Years
-
Gender: All
Inclusion Criteria:
- Obese youth 11-18 years of age with T1D at time of enrollment.
- Lean youth 11-18 years of age with T1D at time of enrollment.
Exclusion Criteria:
- Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and bygenetic/antibody testing).
- History of ongoing infection or antibiotic treatment within the past month;
- History of immune-compromise, recurrent infections, steroid intake (inhaled or oral) or other immunosuppressant use in the past 6 months.
- History of chronic gastrointestinal disease, possible or confirmed celiac disease;
- Participation in any research intervention trials within the past 3 months.
- History of treatment or use of metformin, a type 2 diabetes medication.
Updated on
03 May 2024.
Study ID: 15498
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
